<DOC>
	<DOCNO>NCT00190697</DOCNO>
	<brief_summary>Patients previously enrol LY353381 arm LY353381 oncology trial could enroll `` roll-over '' study exhibit clinical benefit treatment wish continue treatment . Patients monitor safety .</brief_summary>
	<brief_title>A Study LY353381 ( Arzoxifene ) Patients Who Benefitted From This Drug Other Oncology Trials Wished Continue Treatment</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Participation clinical trial LY353381 meet main safety efficacy objective , could otherwise close . Evidence continue benefit LY353381 ( eg . complete response , partial response stable disease symptomatic clinical evidence disease progression ) . Adequate bone marrow reserve , liver renal function , consistent previous LY353381 protocol , recent significant deterioration metabolic condition could affect patient safety compliance protocol ( eg , hypercalcemia ) . Written informed consent patient . Childbearing potential either terminate surgery , radiation , menopause , attenuate use intrauterine contraceptive device barrier method 3 month trial . No concurrent systemic therapy ( immunotherapy , hormone therapy chemotherapy ) cancer . Palliative radiotherapy allow ( eg , pain ) long evidence disease progression . Investigational agent , LY353381 , within 4 week prior study enrollment SERMs also permit . No concurrent use oral contraceptive , GnRH agonists , coumarin ( warfarin ) . No serious concomitant systemic disorder incompatible study ( discretion investigator ) , include predisposition thromboembolic disorder . Must pregnant breastfeeding . Must gap treatment 4 week previous LY353381 study enrollment current study .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>